[Form 3/A] NextCure, Inc. Amended Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

NextCure, Inc. (NXTC) Form 3/A reports that Simcere Zaiming, Inc. directly holds 338,636 shares of NextCure common stock. The amendment adds Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., Hainan Simcere Zaiming Pharmaceutical Co., Ltd., Simcere Pharmaceutical Group Limited, Ren Jinsheng and Tang Renhong as additional reporting persons to the original Form 3 filed by Simcere Zaiming, citing ownership chain and shared voting and investment power. The filing disclaims beneficial ownership except for pecuniary interest and states the amendment only adds reporting persons.

Positive

• Amendment clarifies ownership chain by adding Jiangsu Zaiming, Hainan Zaiming, Simcere Group, Ren Jinsheng and Tang Renhong as reporting persons

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine amendment clarifying ownership structure; no new shares reported.

The Form 3/A corrects reporting-person listings to reflect the ownership chain from Simcere Zaiming to Simcere Group and individual executives. It restates that Simcere Zaiming directly holds 338,636 shares and that other entities and individuals may be deemed indirect beneficial owners with shared voting and investment power. The amendment does not change the reported amount of securities and is administrative in nature.

Corporate Governance Expert

TL;DR: Administrative disclosure improves transparency of who controls reported stake.

The filing documents the control chain: Simcere Zaiming is owned by Jiangsu Zaiming, which is owned by Hainan Zaiming, with Simcere Group as controlling shareholder; Messrs. Ren and Tang hold leadership roles across entities. The explicit disclaimer of beneficial ownership except for pecuniary interest is standard. The amendment appears aimed at EDGAR access and reporting completeness rather than a material change in holdings.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Simcere Zaiming, Inc.

(Last) (First) (Middle)

20 ACORN PARK DR.

(Street)

CAMBRIDGE MA 02140

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/20/2025

3. Issuer Name and Ticker or Trading Symbol
NextCure, Inc. [ NXTC ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)
08/19/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	338,636	I	See footnotes(1)(2)(3)(4)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Simcere Zaiming, Inc.

(Last) (First) (Middle)

20 ACORN PARK DR.

(Street)

CAMBRIDGE MA 02140

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.

(Last) (First) (Middle)

BUILDING 23, NO.699-18,

XUANWU AVENUE, NANJING

(Street)

NANJING CITY, JIANGSU PROVINCE F4 210000

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Hainan Simcere Zaiming Pharmaceutical Co., Ltd.

(Last) (First) (Middle)

NO 20, YAOGUYIHENG ROAD,

XIUYING DISTRICT

(Street)

HAIKOU CITY, HAINAN PROVINCE F4 570100

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Simcere Pharmaceutical Group Ltd

(Last) (First) (Middle)

BUILDING 23, NO.699-18,

XUANWU AVENUE

(Street)

NANJING CITY, JIANGSU PROVINCE F4 210000

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Ren Jinsheng

(Last) (First) (Middle)

BUILDING 23, NO.699-18,

XUANWU AVENUE

(Street)

NANJING CITY, JIANGSU PROVINCE F4 210000

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Tang Renhong

(Last) (First) (Middle)

BUILDING 23, NO.699-18,

XUANWU AVENUE

(Street)

NANJING CITY, JIANGSU PROVINCE F4 210000

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. These securities are directly held by Simcere Zaiming, Inc. ("Simcere Zaiming") and may be deemed to be indirectly beneficially owned by the other reporting persons (the "Reporting Persons").

2. Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. ("Jiangsu Zaiming") is the sole shareholder of Simcere Zaiming, Inc. Hainan Simcere Zaiming Pharmaceutical Co., Ltd. ("Hainan Zaiming") is the sole shareholder of Jiangsu Zaiming. Simcere Pharmaceutical Group Limited ("Simcere Group") is the controlling shareholder of Hainan Zaiming through several intermediate companies. Mr. Ren Jinsheng is the chief executive officer and chairman of the board of directors of Simcere Group and a director of Hainan Zaiming. Mr. Tang Renhong is a director of Simcere Group, the chief executive officer and chairman of the board of directors of Hainan Zaiming, a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming. Messrs. Ren Jinsheng and Tang Renhong may be deemed to be the beneficial owners having shared voting power and shared investment power over the securities described in this footnote.

3. The Reporting Persons disclaim beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that any Reporting Person is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

4. This amendment is being made solely for the purpose of including Jiangsu Zaiming, Hainan Zaiming, Simcere Group, Mr. Ren Jinsheng and Mr. Tang Renhong as additional reporting persons to the Form 3 filed by Simcere Zaiming on 8/19/2025 (the "Original Form"). Although Jiangsu Zaiming, Hainan Zaiming, Simcere Group, Mr. Ren Jinsheng and Mr. Tang Renhong were disclosed in the Original Form, they were unable to be included as reporting persons because they did not have codes for, or lost electronic access to, the EDGAR system at the time. Other than including Jiangsu Zaiming, Hainan Zaiming, Simcere Group, Mr. Ren Jinsheng and Mr. Tang Renhong as additional reporting persons, this form contains no amendment to the Original Form.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney, incorporated by reference to Exhibit 24 to the Schedule 13G filed by Reporting Persons with the Securities and Exchange Commission on August 19, 2025

	Simcere Zaiming, Inc. By: /s/ Renhong Tang, Chief Executive Officer	09/29/2025
	Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. By: /s/ Renhong Tang Director and Attorney-in-Fact	09/29/2025
	Hainan Simcere Zaiming Pharmaceutical Co., Ltd. By: /s/ Renhong Tang Chief Executive Officer and Chairman of the Board of Directors	09/29/2025
	Simcere Pharmaceutical Group Limited By: /s/ Jinsheng Ren Chief Executive Officer and Chairman of the Board of Directors	09/29/2025
	Jinsheng Ren By: /s/ Jinsheng Ren	09/29/2025
	Renhong Tang By: /s/ Renhong Tang	09/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many NextCure (NXTC) shares are reported on the Form 3/A?

The Form 3/A reports 338,636 shares of NextCure common stock beneficially owned by Simcere Zaiming, Inc.

What change does this Form 3/A make to the original filing?

This amendment solely adds additional reporting persons (Jiangsu Zaiming, Hainan Zaiming, Simcere Group, Ren Jinsheng, Tang Renhong) to the original Form 3; it does not change the share amount.

What date triggered the reporting obligation?

The Date of Event requiring the statement is 06/20/2025 as shown in the filing.

Does the filing assert direct beneficial ownership by the added persons?

The filing states the securities are directly held by Simcere Zaiming and that the other reporting persons may be deemed to be indirectly beneficially owned; it also disclaims beneficial ownership except for pecuniary interest.

Were any new derivative securities or transactions reported?

No. Table II for derivative securities contains no reported items; the filing reports only the non-derivative common stock position.